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PLUS CAPECITABINE (L+C)VERSUS CAPECITABINE ONLY
(C-ONLY)
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OBJECTIVES: Lapatinib is an oral small molecule dual targeted
therapy that binds intracellularly to the ATP binding site of the
EGFR and ErbB2 (HER2) receptors. In the EGF100151 trial,
L+C improved time to progression (TTP) and progression free
survival (PFS) vs C-only in women with ErbB2+ MBC who had
received prior therapy including TZ. Following achievement of
the primary endpoint, enrollment was halted, preventing demon-
stration of a signiﬁcant difference in OS. METHODS: To inform
ongoing analyses of the cost-effectiveness of L+C vs. C-only,
Weibull survival functions for PFS and OS were ﬁtted to observed
failure time data from EGF100151 using Accelerated Failure
Time (AFT) regression. Survival function parameters were esti-
mated using a single regression equation for each outcome with
treatment groups entered as an independent variable. Hazard
Ratios (HRs) for progression and death with L+C were assumed
to be proportionate to HRs for C-only. Expected PFS, OS, and
post-progression survival (PPS) were calculated for each group.
The validity of the Weibull model and PH assumption were
assessed using graphical and analytical methods. RESULTS:
Expected PFS, PPS and OS for L+C were 36.89, 43.78, and 80.67
weeks, respectively. Corresponding values for C-only were 22.49,
45.03, 67.47 weeks, respectively. Graphical tests of transformed
survival functions supported use of Weibull distribution. Corre-
lation tests between the ranked failure times and Schoenfeld
residuals, supremum test for proportional hazards assumption,
and comparisons of HRs for L+C vs. C-only by quarter post-
randomization, provided no strong evidence of non-
proportionality. CONCLUSION: Proportional hazards Weibull
survival models are valid for modeling survival time data in
patients with trastuzumab-refractory ErbB2-overexpressing
MBC receiving L+C versus C-only, and suggest that lapatinib
provides substantial beneﬁt in terms of PFS and OS in patients
with ErbB2+ MBC.
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OBJECTIVE: To compare the risk of cancer between Atorvasta-
tin and Simvastatin users. METHODS: Retrospective cohort
study was conducted in Louisiana Medicaid program from
January 1, 1998 through June 30, 2005. Inclusion criteria were
recipients continuously eligible with no more than two months
gap, a paid claim for statin, and at least 40 years of age. Patients
with diagnosis or drug claim for cancer in the washout period
were excluded. Washout period was deﬁned as a period between
index date minus 12 months and index date plus 18 months.
Statin (Atorvastatin or Simvastatin) users were patients with 300
or more days of supply of statin within 18 month period from the
index date. Patients were then followed for at least six months or
until end of study period. A propensity score-based matching
method was used to match both the groups (1:1 match). Users of
Atorvastatin were compared with the users of Simvastatin as to
their risk of cancer. RESULTS: Each group had 1050 recipients
after matching for comparison. Compared with Atorvastatin
users, Simvastatin users experienced similar cancer risk (OR
1.20, 95% C.I. = 0.78–1.82). CONCLUSION: The data from
present study provides evidence that there is no signiﬁcant dif-
ference in risk of cancer between Atorvastatin and Simvastatin
users.
CANCER—Cost Studies
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OBJECTIVE: To evaluate the budget impact to a health plan
after introducing Ixabepilone as a treatment option for meta-
static breast cancer patients who have previously failed Anthra-
cycline and Taxane based regimens. METHODS: The analysis
was conducted from a U.S. payer’s perspective over a three-year
time horizon. The model speciﬁcally considered 2 segments of
MBC patients for which Ixabepilone is indicated: 1) patients
pretreated with Anthracycline and Taxane (AT_p); and 2)
patients pretreated with Anthracycline, Taxane, and Capecitab-
ine (ATC_p). After combining epidemiological data (SEERs,
NCI), market uptake assumptions from market research fore-
casting, and current drug treatment costs (based on WAC price
and average number of treatment cycles a patient received), the
model estimated the incremental budget impact after adopting
Ixabepilone as a treatment option. The model assumed that
during the ﬁrst year, 9.41% of AT_p patients receive Ixabepilone
and Capecitabine combination therapy; and 62.7% of ATC_p
patients are treated with Ixabepilone monotherapy. A plausible
range of parameter values were considered in the sensitivity
analysis. RESULTS: In a hypothetical health plan with approxi-
mately 0.06% of members estimated to be diagnosed with MBC,
it was assumed that 37% were AT_p and 5% were ATC_p
patients. In the year after introduction of Ixabepilone, the overall
incremental cost per member per month (PMPM) was estimated
to be approximately $0.03. For the AT_p patient segment, the
incremental PMPM cost was estimated to be $0.03. However, for
the ATC_p population, the model estimated a savings of $0.002
in PMPM. The incremental cost per treated MBC member per
year is estimated at $545.29 for Year 1, and $640.76 and
$668.01 for Years 2 and 3, respectively. CONCLUSION: In
patients with MBC who have few viable treatment options after
failing AT or ATC treatments, the budgetary impact of adding
Ixabepilone to a health plan was estimated to be minimal.
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OBJECTIVE: To evaluate the HRU in a supplementary medicine
environment in Brazil comparing intravenous (IV) treatments
used in clinical practice. The health resources utilization (HRU)
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in lung cancer treatment is variable according to several items:
the country where the treatment is performed, hospitalization,
administration and drug costs. METHODS: A total of 344 Lung
cancer patients were selected within the records of a private
hospital in Brazil. Of those, 69 patients that received pemetrexed
or docetaxel as second line chemo. The chemotherapy protocols
considered were: Pemetrexed 500mg/m2 every 3 weeks, Doc-
etaxel 75mg/m2 every three weeks, Docetaxel 35mg/m2 weekly (3
times per cycle) and Docetaxel 40mg/m2 weekly (3 times per
cycle). HRU frequency (hospitalization, clinical visits, comple-
mentary examinations, medication, transfusions) related to lung
cancer treatment was reviewed retrospectively from clinical
records. The costs were calculated in dolars (US$) following the
original records for each cycle. The values for neutropenia were
also calculated. RESULTS: Pemetrexed 500mg/m2 every three
weeks was used by 20.5% of the patients; Docetaxel 75 mg/m2
every three weeks by 17.1%; Docetaxel 35mg/m2 weekly (3 times
per cycle) by 8.1% and Docetaxel 40mg/m2 weekly (3 times
per cycle) by 1.1%.The cost of each cycle was U$6897.00 for
Pemetrexed 500mg/m2; US$3041.00 for Docetaxel 75mg/m2;
US$5919.00 for Docetaxel 35mg/m2 and US$6669.00 for Doc-
etaxel 40mg/m2. The costs of neutropenia and febrile neutrope-
nia episodes were respectively US$1310.00 and US$6000.00.
CONCLUSION: Besides the cost of the drug is a mean point in
health resources utilization we have to consider other variables to
have a clear picture of each chemotherapy scheme costs and were
the resources have been used. Since the chance of toxicity is
different for every kind of treatment, all the inputs to reach the
total cost of treatment are necessary.
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OBJECTIVE: To determine the ﬁnancial impact of sorafenib in
the treatment of hepatocellular carcinoma (HCC), the most
common form of liver cancer, from a Canadian provincial drug
plan perspective for 2008–2010. METHODS: A prevalence-
based approach was used to estimate the number of HCC
patients in Canada. Liver cancer prevalence from 2008–2010
was estimated using the GLOBOCAN 2002 database, supple-
mented with actual and projected Canadian liver cancer inci-
dence ﬁgures from 2003–2010, and survival rates for each stage
of HCC. Liver cancer ﬁgures were condensed to HCC ﬁgures as
~90% of liver cancers are HCC. HCC ﬁgures were then seg-
mented using the Barcelona Clinic Liver Cancer staging system
and diagnosis rates provided the clinical community. Age and
geographic distribution patterns, market share assumptions and
provincial drug plan coverage factors were then applied to the
HCC ﬁgures to determine the number of HCC patients eligible
for treatment with sorafenib and coverage from the province.
Drug costs including wholesale and pharmacy mark ups were
multiplied with the median treatment duration and patient
number to determine the ﬁnancial impact of sorafenib.
RESULTS: The prevalence of liver cancer in Canada in 2008 has
been estimated to be 1284 increasing to 1324 by 2009 and 1366
by 2010. Of these an estimated 206 HCC patients will be treated
with sorafenib in 2008, increasing to 321 in 2009 and 438 in
2010. The number of HCC patients treated with sorafenib that
are eligible to receive coverage through their provincial drug plan
are 154, 240 and 328 in 2008, 2009 and 2010 respectively. The
ﬁnancial impact of sorafenib to the provincial drug plans is $3.7
million in 2008, $7.1 million in 2009 and $9.7 million in 2010.
CONCLUSION: The ﬁnancial impact of sorafenib to the pro-
vincial drug plans will range from $3.7 million to $9.7 million
from 2008–2010.
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OBJECTIVE: We sought to systematically review economic
analyses (EAs) of HER2 testing and trastuzumab therapy in all
stages of breast cancer (BC) with speciﬁc attention to the meth-
odological quality, quantiﬁcation of uncertainty and incorpora-
tion of diagnostic test characteristics. METHODS: EAs of
trastuzumab in BC or HER2 diagnosis with either immunohis-
tochemistry or ﬂuorescence in situ hybridisation techniques were
considered. Biosis, Cochrane, CRD, EconLit, Embase, HEED,
Medline and PubMed databases were searched. The reference
lists of each retrieved article, relevant reviews, and abstracts of
the San Antonio Breast Cancer Symposium were hand-searched.
Citations were reviewed in duplicate and relevant articles were
qualitatively rated per Drummond. RESULTS: Twenty studies,
conference abstracts and health technology assessments were
selected for full review from among 641 citations as of December
2007 (reviewer agreement kappa = 0.85). Studies examined tras-
tuzumab in metastatic (7/20) or adjuvant (10/20) settings or had
a testing focus (4/20). HER2 diagnosis strategy and trastuzumab
treatment were evaluated jointly in only one study. Few decision
models were calibrated against epidemiological data (3/20).
Probabilistic sensitivity analysis was infrequently used to charac-
terise uncertainty (3/20) and decision uncertainty in the form of
cost-effectiveness acceptability curves was presented in a single
study. The overall reported quality of EAs was comparatively
poor. CONCLUSION: Testing and treatment were rarely exam-
ined in tandem, despite a 2004 EA addressing this very issue in
metastatic disease. Given the controversy around trastuzumab
funding in many jurisdictions, the need for adequate attention to
testing and uncertainty analysis is not met in the literature.
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CANCERVACCINES IN CANADA USING MULTIPLE
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Demarteau N1,Anonychuk AM2, Standaert B1
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OBJECTIVE: Two vaccines against cervical cancer are now
available. One reduces the burden of genital warts; with the other
the model estimates it may have better cross-protection against
oncogenic non-vaccine HPV-types. We aimed to understand the
extent to which cross-protection could have an equivalent cost
impact and the likelihood this would occur. METHODS: A
population model was developed in Excel(r) to evaluate the
expected annual health care cost of protecting cervical diseases
with vaccines against speciﬁc HPV-types. The type-speciﬁc
vaccine effect was assessed on the number of abnormal pap
smears, pre-cancer lesions, genital warts and cervical cancer cases
prevented. Vaccine effect was calculated by multiplying the pro-
portion of HPV-types per lesion, as reported in the literature, by
a range of vaccine efﬁcacy values. A health care perspective was
selected, with unit costs (2006 CDN$) for each intervention
obtained from ofﬁcial tariff data. No discounting was applied as
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